|
4 Companies |
|
4 Products |
|
4 Products |
|
6 Mechanisms of Action |
|
4 Trials |
|
31 News |
|
- | Trial completion, Enrollment change: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Feb 20, 2018
P=N/A, N=63, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed | N=45 --> 63
- | Trial completion, Enrollment change, Trial primary completion date: T2T@PSU: Tweens to Teens Project at Penn State (clinicaltrials.gov) - Jan 8, 2018
P=N/A, N=188, Completed, Sponsor: Penn State University
Active, not recruiting --> Completed | N=45 --> 63 Recruiting --> Completed | N=300 --> 188 | Trial primary completion date: Jul 2011 --> Jul 2013
- | NN1213 / Novo Nordisk
Trial completion: Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=61, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Completed | N=300 --> 188 | Trial primary completion date: Jul 2011 --> Jul 2013 Recruiting --> Completed
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion, Trial primary completion date: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 6, 2016
P2, N=8, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016
- Enrollment closed: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Jun 30, 2016
P=N/A, N=45, Active, not recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Dec 2016 Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=170, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Phase classification: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Apr 21, 2016
P2, N=8, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed | Trial primary completion date: Feb 2016 --> Sep 2015 Phase classification: P1/2 --> P2
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Enrollment closed: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Dec 21, 2015
P1/2, N=8, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Phase classification: P1/2 --> P2 Recruiting --> Active, not recruiting
- verucerfont (GSK-561679) / GSK
Enrollment change, Trial withdrawal: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 11, 2015
P1, N=0, Withdrawn, Sponsor: Neurocrine Biosciences
Recruiting --> Active, not recruiting N=15 --> 0 | Recruiting --> Withdrawn
- Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=180, Recruiting, Sponsor: Assistance Publique - H
N=15 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Oct 2015 --> Feb 2016
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial primary completion date: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Mar 11, 2015
P1/2, N=8, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Oct 2015 --> Feb 2016 Trial primary completion date: Dec 2016 --> Jun 2017
- verucerfont (GSK-561679) / GSK
Enrollment open: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Mar 5, 2015
P1, N=15, Recruiting, Sponsor: Neurocrine Biosciences
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | verucerfont (GSK-561679) / GSK
New P1 trial: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jan 29, 2015
P1, N=15, Not yet recruiting, Sponsor: Neurocrine Biosciences
- Enrollment open, Trial primary completion date: Decision Support for Parents Receiving Information About Child's Rare Disease (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=45, Recruiting, Sponsor: University of Michigan
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Mar 2016
- Trial primary completion date: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=180, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Mar 2016 Trial primary completion date: May 2014 --> Oct 2015
- | Efmody (hydrocortisone modified release) / Neurocrine
Biomarker, Trial completion: Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort (clinicaltrials.gov) - Jan 5, 2014
P2, N=16, Completed, Sponsor: Diurnal Limited
Trial primary completion date: May 2014 --> Oct 2015 Active, not recruiting --> Completed
- Trial withdrawal: Gene Polymorphisms Influencing Steroid Synthesis and Action (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Schleswig-Holstein
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Gene Polymorphisms Influencing Steroid Synthesis and Action (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Schleswig-Holstein
Recruiting --> Withdrawn N=500 --> 0
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
New P1/2 trial: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia (clinicaltrials.gov) - May 19, 2013
P1/2, N=8, Recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
- Clinical: cardiohcs: Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Mar 6, 2013
P=N/A, N=180, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- | Efmody (hydrocortisone modified release) / Neurocrine
Biomarker, New P2 trial: Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort (clinicaltrials.gov) - Nov 26, 2012
P2, N=16, Completed, Sponsor: Diurnal Limited
- Enrollment change: CaHASE: Study of UK Adults With Congenital Adrenal Hyperplasia. (clinicaltrials.gov) - Jun 7, 2012
P=N/A, N=25, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
N=500 --> 0 N=200 --> 25
- Trial completion: CaHASE: Study of UK Adults With Congenital Adrenal Hyperplasia. (clinicaltrials.gov) - Jun 7, 2012
P=N/A, N=25, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
N=200 --> 25 Active, not recruiting --> Completed